In conclusion, vWF acts as a simple prognostic biomarker in anticoagulated AF patients and, whilst addition of vWF levels to the CHA2DS2-VASc and the HAS-BLED scores statistically improved prediction for some endpoints, the absolute changes and clinical value or impact on practical decision-making was minimal. This evidence concerns the gene VWF and atrial fibrillation.